Association of apolipoprotein D with chronic inflammation, diabetes, diabetic complications and atherosclerosis

Association of apolipoprotein D with chronic inflammation, diabetes, diabetic complications and atherosclerosis - ApoD and diabetic complications

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000026608

Enrollment

400

Registered

2017-03-21

Start date

2017-03-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who are not under insulin therapy.

Exclusion criteria

Exclusion criteria: Those who suffer from chronic or acute inflammatory diseases (collagen diseases, acute inflammatory diseases during the past 4 weeks, etc.). Those who suffer from malignant diseases. Those who are pregnant, breast-feeding, or have the probability of pregnancy. Those whose HbA1c values are more than 9.0% during the past 3 months. Those who cannot give us a voluntary informed consent to the study.

Design outcomes

Primary

Measure	Time frame
In the cross-sectional analysis, we will examine the relationship between apoD levels and insulin resistance (HOMA-IR, adiponection levels, etc.), markers for inflammation (CRP, TNFa, etc.), biochemical data, diabetic complication and status of atherosclerotic diseases. Afterwards, patients are followed periodically (one, 3, 6 and 9 years later), and as a longitudinal study, we will examine the influence of apoD and other markers (inflammation, insulin resistance, biochemical data) on the progression of diabetic complications and atherosclerosis.	—

Measure

Time frame

In the cross-sectional analysis, we will examine the relationship between apoD levels and insulin resistance (HOMA-IR, adiponection levels, etc.), markers for inflammation (CRP, TNFa, etc.), biochemical data, diabetic complication and status of atherosclerotic diseases. Afterwards, patients are followed periodically (one, 3, 6 and 9 years later), and as a longitudinal study, we will examine the influence of apoD and other markers (inflammation, insulin resistance, biochemical data) on the progression of diabetic complications and atherosclerosis.

—

Countries

Japan

Contacts

Public ContactKazuhisa Tsukamoto

Teikyo University Department of Internal Medicine

kazuhisa-tky@umin.ac.jp03-3964-1211

Outcome results